Intellia Secures $400M Non-Dilutive Debt Facility with OrbiMed
NTLA sits 61% above its 52-week low of $7.95.
Summary
Intellia has secured a $400 million non-dilutive senior secured term loan facility with OrbiMed, with $75 million funded upfront and the remainder tied to milestones. This financing extends the company's cash runway without shareholder dilution, supporting the planned U.S. approval and commercial launch of lonvo-z for hereditary angioedema. The deal follows positive Phase 3 results for lonvo-z reported in June and Q2 2026 financials that extended cash runway into 2028. The non-dilutive structure is a positive signal, as it avoids equity issuance at current depressed prices. Key watch items include achievement of the milestones required to access the additional $225 million in tranches and the FDA decision on lonvo-z.
At the time of this announcement, NTLA was trading at $12.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $7.95 to $28.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.